jablongo 3 hours ago

If you pair this with genetically engineered hypoimmune islet cells to avoid needing to suppress immune system you could have a viable cure. https://ir.sana.com/news-releases/news-release-details/sana-...

  • y-curious 2 hours ago

    Yes, immunity is the big problem. You probably need to replenish the islets either way. Also, I don't think doctors would be content giving someone that isn't suppressed this without loads of research.

cassidius 3 hours ago

More groundbreaking research funded by the NIH. It's sad to think about how much the US is going to lose with the arbitrary slashing and burning and purging.

  • asciii 2 hours ago

    Don't worry they'll take credit for saving this

karim79 6 hours ago

So it's a trade-off between increased risk of cancer[0] and the consequences of type 1 diabetes? Doesn't sound like a fun trade-off but I don't know anything.

[0] https://www.cancer.gov/about-cancer/causes-prevention/risk/i...

  • gsf_emergency_2 3 hours ago

    There was a recent "breakthrough" involving the same, except with patient's own stem cells, & not just in mice.

    https://stemcellres.biomedcentral.com/articles/10.1186/s1328...

    That would mitigate the cancer risk, since immunosuppression would not be required?

    • klipt 4 minutes ago

      > patient's own stem cells

      > immunosuppression would not be required

      I don't think that's how Type I Diabetes works. People get Type I Diabetes because their immune system attacked their own insulin producing cells in the first place. It's an autoimmune disease. So if you replenish those cells, they'll just get attacked again.

  • arcticbull 3 hours ago

    If you take rapamycin or a rapalog as an anti-rejection drug, your risk of cancer is lower - not higher - because it's not actually an immune suppressant so much as a drug that prevents hyperimmunity. [1] Other immune suppressants work differently but it's not a blanket true statement that taking anti-rejection drugs will increase your risk of cancer. Depends what you take.

    You can read the section in [1] titled "Cancer prevention in humans."

    > Starting from 2004, numerous studies demonstrated that rapamycin and everolimus reduced the incidence of various cancers in organ transplant patients.

    [edit] In fact in addition to its use as an anti-rejection medication, rapamycin is used as chemotherapy to treat certain forms of cancer.

    [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC10103596/

  • Trasmatta 6 hours ago

    Type 1 diabetic here: you're right, it's a bad tradeoff. We already can do pancreas transplants for T1D, but the reason it's very uncommon is that immunosuppressants are a very bad tradeoff. Insulin treatment is preferred in the vast majority of cases.

    Stuff like this will never be a breakthrough until it doesn't need immunosuppressants. The best advancements in diabetes treatment will most likely continue to be on closed loop artificial pancreas systems.

    • nextos 5 hours ago

      Insulin-specific immunotherapies are currently under development. We will soon be able to restore tolerance to insulin, and other pancreatic antigens such as GAD-65, without the need for broad immunosupressants. Ideally, this should stop β cell destruction and conversion to T1D from auto-antibody positive status, as well as facilitate islet transplants with minimal side effects for those that are already T1D patients.

    • karim79 6 hours ago

      I'm sorry for your plight and I genuinely hope there will be a much more tenable solution in the near future.

Trasmatta 4 days ago

> To prevent islet rejection, immune-suppressing drugs are given over the long term.

This makes it a non starter. Immunosuppressants are generally considered a worse quality of life than insulin treatment. That's why pancreas transplants are generally only done for type 1 diabetics if they are already on immunosuppressants.

  • Terr_ 6 hours ago

    I'm hopeful that someday we'll have a good system for "caging" cells to prevent an immune response (in either direction) while also permitting the visitors to sustain themselves with blood nutrients and regulate hormones or clean waste.

    Sort of like the role of the blood-brain barrier, or maybe a placenta.

    • Trasmatta 6 hours ago

      Yes! I think there was some work being done with a islet transplant like that. I'm not sure of the details though - it's probably a long way off, if it works.

  • pixl97 6 hours ago

    Yep. The hard, if not kear impossible part will be just resetting the one part of the immune system attacking the islets without turning off or resetting the immune system.

    • mlhpdx 5 hours ago

      The promising part here is that someday it will be possible to take stem cells from a patient and specialize them to islet cells. Similar to what they’re doing here with vascular cells. It’s far too expensive at the moment, but ultimately the process will be improved and refined, and the costs will come down. At least that’s my hope for a cure.

    • im3w1l 5 hours ago

      Easiest method may be to nuke the immune system and put a new one in place. As the immune system consists of several parts it may be sufficient to just replace one of them.

  • markdog12 4 hours ago

    Note this is for the current common approach, not the new approach.

hereme888 5 hours ago

The author claimed no competing interests, yet his research is used for the patents. We'll see how it plays out in the real world after all the stardust settles.

ThrowawayTestr 2 hours ago

Awesome. Hopefully when this is perfected they'll be enough pancreases to cure everyone. My pancreas is ear marked for my sibling should I become an eligible donor.

WindyMiller 6 hours ago

...IN MICE

  • mlhpdx 5 hours ago

    And not just mice, but mice engineered with “T1D like” conditions. Human testing too early is certainly undesirable but these studies with mice, while necessary and important, are nothing newsworthy for the general public (but good for fundraising for follow up work).

  • strkitten 2 hours ago

    Indeed, I would appreciate if the title were updated to reflect that the subjects were mice, not humans. It’s a bit misleading.

  • bitwize 4 hours ago

    Late last year a woman's T1D was put into remission using beta cells derived from her own stem cells: https://www.nature.com/articles/s41591-024-03394-9

    She was on immunosuppressants, so how long the new beta cells would last without those is still an open question. Other similar, ongoing trials are showing promising results.

  • _carbyau_ 5 hours ago

    Yeah! How amazing is that! Reversing type 1 diabetes anywhere is amazing.

    A way to go until it becomes an option for humans. And then way more to go until it becomes a preferred option.

    But this is great news.

    • jfengel 5 hours ago

      Not if it requires immune suppressants. They can already transplant whole pancreases. They rarely do because the resulting lifetime of immune suppression is worse than the quite effective insulin injections.

      Any research could pay big benefits eventually but this is far from "great news". It's a step forward along a path that is actually well behind the others.

      • _carbyau_ 4 hours ago

        I think you and I have a different approach to science.

        I see research as not entirely linear and think that multiple paths should be funded. Most paths won't be "the definitive answer" but add capability, or definitively rule out an approach, that can be used in other scenarios. TheFineArticle shows a different path to the others and they made a great step on it - that seems like money well spent to me.

        What I get from reading your post is that it's some kind of race and only the one currently winning should be lauded. I'm not sure if that is what you intend to communicate though.

      • energy123 4 hours ago

        Rapamycin increases lifespan of mice more than any other known compound.